Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Multicentric non-randomized phase II opened prospective study (10 centres involved).
Primary endpoint:
- To evaluate the kinetics of B-cell depletion by rituximab and its pharmacokinetics in
patients treated with rituximab in association with plasma exchanges.
Secondary endpoints:
- To evaluate the tolerance of rituximab, the volume of plasma and the number of plasma
exchange sessions required to achieve a durable complete remission, and to determinate
the duration of B-cell depletion.
- To evaluate the incidence of persistent severe acquired ADAMTS13 deficiency following
treatment with rituximab, as well as the incidence of relapses.